Monitoring of dipeptidyl peptidase-IV (DPP-IV) activity in patients with mucopolysaccharidoses types I and II on enzyme replacement therapy ‿Results of a pilot study
详细信息 查看全文
- 作者：Katarzyna Hetmańczyk1 ; Małgorzata Bednarska-Makaruk1 ; Karolina Kierus2 ; Sylwia Murawska-Izdebska3 ; Dorota Piekutowska-Abramczuk4 ; Bożena Pilch5 ; Anna Tylki-Szymańska6 ; Agnieszka Ługowska1 ; alugipin@yahoo.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Mucopolysaccharidosis type I ; Mucopolysaccharidosis type II ; DPP-IV ; Enzyme replacement therapy ; Biomarker
- 刊名：Clinical Biochemistry
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：49
- 期：6
- 页码：458-462
- 全文大小：605 K
文摘
- •
DPP-IV activity was 3.5-fold higher in MPS I or II patients before ERT than in controls.
- •
In MPS patients on ERT, DPP-IV activity was labile; no declining tendency was observed.
- •
DPP-IV activity is a valuable biomarker distinguishing MPS from healthy individuals.
- •
DPP-IV is unsuitable for the monitoring of ERT effectiveness.